Boston Scientific Corp. vs. GLOBUS MEDICAL INC
Boston Scientific Corp. (BSX) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| BSX | GMED | |
|---|---|---|
| Market Cap | $75.11 billion | $11.53 billion |
| Revenue (TTM) | $21.00 billion | — |
| Net Income (TTM) | $3.67 billion | — |
BSX leads on 1 of 1 size & scale factors.
Valuation
| BSX | GMED | |
|---|---|---|
| P/E Ratio | 20.98 | — |
| Price / Book | 2.98 | 2.42 |
| Price / Sales | 3.58 | — |
GMED leads on 1 of 1 valuation factors.
Profitability
| BSX | GMED | |
|---|---|---|
| Net Margin | 17.47% | — |
| Return on Equity | 14.58% | — |
BSX and GMED split the profitability factors evenly.
Risk & Sentiment
| BSX | GMED | |
|---|---|---|
| Short Interest | 0.72% | 3.12% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, GMED overview, GMED financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.